A Phase 2 Exploratory Study to evaluate efficacy and safety of CS-3150 in Japanese Hypertensive Patients with Moderate Kidney Dysfunction

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222831

Enrollment

Registered

2015-04-24

Start date

2015-05-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension with moderate kidney dysfunction

Interventions

investigational material(s) Generic name etc : CS-3150 INN of investigational material : Esaxerenone Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investigational mat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Male and female subjects aged 20 years or older and 80 years or younger at informed consent 2)Subjects with hypertension (Sitting SBP >= 140 mmHg and = 80 mmHg and = 30 mL/min/1.73 m2 and < 60 mL/min/1.73 m2

Exclusion criteria

Exclusion criteria: 1)Secondary hypertension (except renoparenchymal hypertension) or malignant hypertension 2)Diabetes mellitus with albuminuria 3)Serum potassium level = 5.1 mEq/L 4)Subjects under Insulin treatment 5)Subjects under or pre-planned for hemodialysis

Design outcomes

Primary

Measure	Time frame
safety efficacy - Change from baseline in sitting systolic and diastolic blood pressure - Adverse events	—

Secondary

Measure	Time frame
safety efficacy - Time course of sitting systolic and diastolic blood pressure - Proportion of patients achieving sitting blood pressure control - Change from baseline in urinary albumin creatinine ratio - Change in serum potassium	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026